ID   STK38_HUMAN             Reviewed;         465 AA.
AC   Q15208; Q503A1;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 203.
DE   RecName: Full=Serine/threonine-protein kinase 38;
DE            EC=2.7.11.1;
DE   AltName: Full=NDR1 protein kinase;
DE   AltName: Full=Nuclear Dbf2-related kinase 1;
GN   Name=STK38 {ECO:0000312|EMBL:AAH12085.1};
GN   Synonyms=NDR1 {ECO:0000303|PubMed:7761441};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAA84485.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-118.
RC   TISSUE=Fetal brain {ECO:0000312|EMBL:CAA84485.1};
RX   PubMed=7761441; DOI=10.1073/pnas.92.11.5022;
RA   Millward T.A., Cron P., Hemmings B.A.;
RT   "Molecular cloning and characterization of a conserved nuclear
RT   serine/threonine protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:5022-5026(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3] {ECO:0000312|EMBL:AAH12085.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta, and Uterus {ECO:0000312|EMBL:AAH12085.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-17; 25-44; 51-63; 72-78; 82-97; 110-118; 122-159;
RP   182-239; 248-266; 277-301; 334-391; 394-402 AND 437-454, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Calvo F., Kolch W.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [5] {ECO:0000305}
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT THR-74; SER-281 AND
RP   THR-444, AND MUTAGENESIS OF THR-74; LYS-118; SER-281 AND THR-444.
RX   PubMed=12493777; DOI=10.1074/jbc.m210590200;
RA   Tamaskovic R., Bichsel S.J., Rogniaux H., Stegert M.R., Hemmings B.A.;
RT   "Mechanism of Ca2+-mediated regulation of NDR protein kinase through
RT   autophosphorylation and phosphorylation by an upstream kinase.";
RL   J. Biol. Chem. 278:6710-6718(2003).
RN   [6] {ECO:0000305}
RP   ACTIVITY REGULATION, AND INTERACTION WITH MOB1 AND MOB2.
RX   PubMed=15067004; DOI=10.1074/jbc.m401999200;
RA   Devroe E., Erdjument-Bromage H., Tempst P., Silver P.A.;
RT   "Human Mob proteins regulate the NDR1 and NDR2 serine-threonine kinases.";
RL   J. Biol. Chem. 279:24444-24451(2004).
RN   [7] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ACTIVITY REGULATION,
RP   AND INTERACTION WITH MOB1 AND MOB2.
RX   PubMed=15197186; DOI=10.1074/jbc.m404542200;
RA   Bichsel S.J., Tamaskovic R., Stegert M.R., Hemmings B.A.;
RT   "Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase by
RT   the hMOB1 protein.";
RL   J. Biol. Chem. 279:35228-35235(2004).
RN   [8]
RP   ISGYLATION.
RX   PubMed=16884686; DOI=10.1016/j.bbrc.2006.07.076;
RA   Takeuchi T., Inoue S., Yokosawa H.;
RT   "Identification and Herc5-mediated ISGylation of novel target proteins.";
RL   Biochem. Biophys. Res. Commun. 348:473-477(2006).
RN   [9]
RP   INTERACTION WITH STK3/MST2 AND MOBKL1B, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION BY STK3/MST2.
RX   PubMed=18362890; DOI=10.1038/onc.2008.66;
RA   Hirabayashi S., Nakagawa K., Sumita K., Hidaka S., Kawai T., Ikeda M.,
RA   Kawata A., Ohno K., Hata Y.;
RT   "Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to
RT   form the scaffold to activate nuclear Dbf2-related kinase 1.";
RL   Oncogene 27:4281-4292(2008).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAP3K1 AND MAP3K2.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase 38
RT   (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   CAUTION.
RX   PubMed=19377461; DOI=10.1038/nature07954;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "GlcNAcylation of a histone methyltransferase in retinoic-acid-induced
RT   granulopoiesis.";
RL   Nature 459:455-459(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-264, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-264, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   CAUTION, AND RETRACTION NOTICE OF PUBMED:23186163.
RX   PubMed=24336203; DOI=10.1038/nature12896;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "Retraction: GlcNAcylation of a histone methyltransferase in retinoic-acid-
RT   induced granulopoiesis.";
RL   Nature 505:574-574(2014).
RN   [18] {ECO:0000305}
RP   STRUCTURE BY NMR OF 62-84, ACTIVITY REGULATION, AND INTERACTION WITH S100B.
RX   PubMed=14661952; DOI=10.1021/bi035089a;
RA   Bhattacharya S., Large E., Heizmann C.W., Hemmings B.A., Chazin W.J.;
RT   "Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into S100
RT   target specificity and activation of the kinase.";
RL   Biochemistry 42:14416-14426(2003).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-18; ASN-145 AND ARG-267.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Negative regulator of MAP3K1/2 signaling. Converts MAP3K2
CC       from its phosphorylated form to its non-phosphorylated form and
CC       inhibits autophosphorylation of MAP3K2. {ECO:0000269|PubMed:12493777,
CC       ECO:0000269|PubMed:15197186, ECO:0000269|PubMed:17906693,
CC       ECO:0000269|PubMed:7761441}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by binding of S100B which releases
CC       autoinhibitory N-lobe interactions, enabling ATP to bind and the
CC       autophosphorylation of Ser-281. Thr-444 then undergoes calcium-
CC       dependent phosphorylation by STK24/MST3. Interactions between
CC       phosphorylated Thr-444 and the N-lobe promote additional structural
CC       changes that complete the activation of the kinase. Autoinhibition is
CC       also released by the binding of MOB1/MOBKL1A and MOB2/HCCA2 to the N-
CC       terminal of STK38. {ECO:0000269|PubMed:12493777,
CC       ECO:0000269|PubMed:14661952, ECO:0000269|PubMed:15067004,
CC       ECO:0000269|PubMed:15197186}.
CC   -!- SUBUNIT: Homodimeric S100B binds two molecules of STK38
CC       (PubMed:14661952). Interacts with MOB1 and MOB2 (PubMed:15067004,
CC       PubMed:15197186). Interacts with MAP3K1 and MAP3K2 (via the kinase
CC       catalytic domain) (PubMed:17906693). Forms a tripartite complex with
CC       MOBKL1B and STK3/MST2 (PubMed:18362890). Interacts with MICAL1; leading
CC       to inhibit the protein kinase activity by antagonizing activation by
CC       MST1/STK4 (By similarity). {ECO:0000250|UniProtKB:Q91VJ4,
CC       ECO:0000269|PubMed:14661952, ECO:0000269|PubMed:15067004,
CC       ECO:0000269|PubMed:15197186, ECO:0000269|PubMed:17906693,
CC       ECO:0000269|PubMed:18362890}.
CC   -!- INTERACTION:
CC       Q15208; P49407: ARRB1; NbExp=3; IntAct=EBI-458376, EBI-743313;
CC       Q15208; P32121: ARRB2; NbExp=3; IntAct=EBI-458376, EBI-714559;
CC       Q15208; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-458376, EBI-11524452;
CC       Q15208; Q03135: CAV1; NbExp=3; IntAct=EBI-458376, EBI-603614;
CC       Q15208; P08238: HSP90AB1; NbExp=2; IntAct=EBI-458376, EBI-352572;
CC       Q15208; Q9H8S9: MOB1A; NbExp=3; IntAct=EBI-458376, EBI-748229;
CC       Q15208; P16333: NCK1; NbExp=3; IntAct=EBI-458376, EBI-389883;
CC       Q15208; P30086: PEBP1; NbExp=3; IntAct=EBI-458376, EBI-716384;
CC       Q15208; P02638: S100B; Xeno; NbExp=3; IntAct=EBI-458376, EBI-458452;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with highest levels observed
CC       in peripheral blood leukocytes. {ECO:0000269|PubMed:15197186,
CC       ECO:0000269|PubMed:7761441}.
CC   -!- PTM: ISGylated. {ECO:0000305|PubMed:16884686}.
CC   -!- PTM: Phosphorylated by STK3/MST2 and this is enhanced by MOBKL1B.
CC       {ECO:0000269|PubMed:12493777, ECO:0000269|PubMed:18362890}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be part of the MLL5-L complex, at
CC       least composed of KMT2E, STK38, PPP1CA, PPP1CB, PPP1CC, HCFC1, ACTB and
CC       OGT (PubMed:19377461). However, the corresponding article has been
CC       retracted (PubMed:24336203). {ECO:0000269|PubMed:19377461,
CC       ECO:0000269|PubMed:24336203}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z35102; CAA84485.1; -; mRNA.
DR   EMBL; Z85986; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012085; AAH12085.1; -; mRNA.
DR   EMBL; BC095413; AAH95413.1; -; mRNA.
DR   CCDS; CCDS4822.1; -.
DR   PIR; I38133; I38133.
DR   RefSeq; NP_001292031.1; NM_001305102.1.
DR   RefSeq; NP_009202.1; NM_007271.3.
DR   RefSeq; XP_006715051.1; XM_006714988.3.
DR   RefSeq; XP_006715052.1; XM_006714989.3.
DR   PDB; 1PSB; NMR; -; C/D=62-87.
DR   PDB; 6BXI; X-ray; 2.20 A; A/B=82-414.
DR   PDBsum; 1PSB; -.
DR   PDBsum; 6BXI; -.
DR   AlphaFoldDB; Q15208; -.
DR   BMRB; Q15208; -.
DR   SMR; Q15208; -.
DR   BioGRID; 116457; 124.
DR   CORUM; Q15208; -.
DR   IntAct; Q15208; 60.
DR   MINT; Q15208; -.
DR   STRING; 9606.ENSP00000229812; -.
DR   BindingDB; Q15208; -.
DR   ChEMBL; CHEMBL1075155; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q15208; -.
DR   iPTMnet; Q15208; -.
DR   MetOSite; Q15208; -.
DR   PhosphoSitePlus; Q15208; -.
DR   BioMuta; STK38; -.
DR   DMDM; 56749457; -.
DR   EPD; Q15208; -.
DR   jPOST; Q15208; -.
DR   MassIVE; Q15208; -.
DR   MaxQB; Q15208; -.
DR   PaxDb; Q15208; -.
DR   PeptideAtlas; Q15208; -.
DR   PRIDE; Q15208; -.
DR   ProteomicsDB; 60489; -.
DR   Antibodypedia; 29688; 448 antibodies from 32 providers.
DR   DNASU; 11329; -.
DR   Ensembl; ENST00000229812.8; ENSP00000229812.7; ENSG00000112079.9.
DR   GeneID; 11329; -.
DR   KEGG; hsa:11329; -.
DR   MANE-Select; ENST00000229812.8; ENSP00000229812.7; NM_007271.4; NP_009202.1.
DR   UCSC; uc003omh.3; human.
DR   CTD; 11329; -.
DR   DisGeNET; 11329; -.
DR   GeneCards; STK38; -.
DR   HGNC; HGNC:17847; STK38.
DR   HPA; ENSG00000112079; Low tissue specificity.
DR   MIM; 606964; gene.
DR   neXtProt; NX_Q15208; -.
DR   OpenTargets; ENSG00000112079; -.
DR   PharmGKB; PA38251; -.
DR   VEuPathDB; HostDB:ENSG00000112079; -.
DR   eggNOG; KOG0605; Eukaryota.
DR   GeneTree; ENSGT00940000153544; -.
DR   HOGENOM; CLU_000288_67_0_1; -.
DR   InParanoid; Q15208; -.
DR   OMA; YTYKKSD; -.
DR   OrthoDB; 759391at2759; -.
DR   PhylomeDB; Q15208; -.
DR   TreeFam; TF105337; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q15208; -.
DR   Reactome; R-HSA-9013418; RHOBTB2 GTPase cycle.
DR   Reactome; R-HSA-9013422; RHOBTB1 GTPase cycle.
DR   SignaLink; Q15208; -.
DR   SIGNOR; Q15208; -.
DR   BioGRID-ORCS; 11329; 15 hits in 1066 CRISPR screens.
DR   ChiTaRS; STK38; human.
DR   EvolutionaryTrace; Q15208; -.
DR   GeneWiki; STK38; -.
DR   GenomeRNAi; 11329; -.
DR   Pharos; Q15208; Tchem.
DR   PRO; PR:Q15208; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q15208; protein.
DR   Bgee; ENSG00000112079; Expressed in palpebral conjunctiva and 206 other tissues.
DR   ExpressionAtlas; Q15208; baseline and differential.
DR   Genevisible; Q15208; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0036211; P:protein modification process; IDA:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   IDEAL; IID00172; -.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cytoplasm;
KW   Direct protein sequencing; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.4"
FT   CHAIN           2..465
FT                   /note="Serine/threonine-protein kinase 38"
FT                   /id="PRO_0000086718"
FT   DOMAIN          89..382
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000312|EMBL:CAA84485.1"
FT   DOMAIN          383..455
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          62..87
FT                   /note="Interaction with S100B"
FT                   /evidence="ECO:0000269|PubMed:14661952"
FT   ACT_SITE        212
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         95..103
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:O95835,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         118
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:12493777, ECO:0000269|PubMed:7761441"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.4"
FT   MOD_RES         74
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   MOD_RES         264
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         281
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   MOD_RES         444
FT                   /note="Phosphothreonine; by STK24/MST3"
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   VARIANT         18
FT                   /note="E -> K (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041196"
FT   VARIANT         145
FT                   /note="D -> N (in dbSNP:rs56005153)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041197"
FT   VARIANT         267
FT                   /note="K -> R (in dbSNP:rs56105564)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041198"
FT   MUTAGEN         74
FT                   /note="T->A: Decreases autophosphorylation and kinase
FT                   activity. Reduced binding of S100B."
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   MUTAGEN         118
FT                   /note="K->A: Loss of autophosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12493777,
FT                   ECO:0000269|PubMed:7761441"
FT   MUTAGEN         281
FT                   /note="S->A: Loss of autophosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   MUTAGEN         444
FT                   /note="T->A: Decreases autophosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12493777"
FT   HELIX           74..85
FT                   /evidence="ECO:0007829|PDB:1PSB"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          89..98
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          101..108
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   TURN            109..111
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          114..121
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           122..124
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           128..144
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          152..157
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          159..166
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           174..181
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           186..205
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           215..217
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           239..241
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           243..246
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           257..260
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           264..273
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           275..280
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           291..294
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           303..317
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           327..335
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           337..340
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           351..360
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           364..366
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   TURN            368..371
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           374..377
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           380..382
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:6BXI"
FT   HELIX           390..392
FT                   /evidence="ECO:0007829|PDB:6BXI"
SQ   SEQUENCE   465 AA;  54190 MW;  7262221DBFFAF83C CRC64;
     MAMTGSTPCS SMSNHTKERV TMTKVTLENF YSNLIAQHEE REMRQKKLEK VMEEEGLKDE
     EKRLRRSAHA RKETEFLRLK RTRLGLEDFE SLKVIGRGAF GEVRLVQKKD TGHVYAMKIL
     RKADMLEKEQ VGHIRAERDI LVEADSLWVV KMFYSFQDKL NLYLIMEFLP GGDMMTLLMK
     KDTLTEEETQ FYIAETVLAI DSIHQLGFIH RDIKPDNLLL DSKGHVKLSD FGLCTGLKKA
     HRTEFYRNLN HSLPSDFTFQ NMNSKRKAET WKRNRRQLAF STVGTPDYIA PEVFMQTGYN
     KLCDWWSLGV IMYEMLIGYP PFCSETPQET YKKVMNWKET LTFPPEVPIS EKAKDLILRF
     CCEWEHRIGA PGVEEIKSNS FFEGVDWEHI RERPAAISIE IKSIDDTSNF DEFPESDILK
     PTVATSNHPE TDYKNKDWVF INYTYKRFEG LTARGAIPSY MKAAK
//
